相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Three decades of transplantation for chronic myeloid leukemia: what have we learned?
Jiri Pavlu et al.
BLOOD (2011)
Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations
Elias Jabbour et al.
BLOOD (2011)
Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV
Susanne Saussele et al.
BLOOD (2010)
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon et al.
LANCET ONCOLOGY (2010)
Current role of stem cell transplantation in chronic myeloid leukaemia
Alois Gratwohl et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2009)
Treatment strategies for CML
John M. Goldman
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2009)
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
Michele Baccarani et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
A. Hochhaus et al.
LEUKEMIA (2009)
Graft-versus-disease effect following allogeneic transplantation for acute leukaemia
Jacob M. Rowe
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2008)
European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor
David Marin et al.
BLOOD (2008)
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study
Richard A. Larson et al.
BLOOD (2008)
Molecular monitoring in chronic myeloid leukemia - Response to tyrosine kinase inhibitors and prognostic implications
Elias Jabbour et al.
CANCER (2008)
Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analysis
Hugues de Lavallade et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib
A. Hochhaus et al.
LEUKEMIA (2008)
Mild renal dysfunction associated with incident coronary artery disease in young males
David Pereg et al.
EUROPEAN HEART JOURNAL (2008)
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
Hagop M. Kantarjian et al.
BLOOD (2007)
How I treat chronic myeloid leukemia in the imatinib era
John M. Goldman
BLOOD (2007)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Michele Baccarani et al.
BLOOD (2006)
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Moshe Talpaz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
EBMT activity survey 2004 and changes in disease indication over the past 15 years
A. Gratwohl et al.
BONE MARROW TRANSPLANTATION (2006)
Management of chronic myeloid leukaemia in relapse following donor lymphocyte infusion induced remission: a retrospective study of the clinical trials committee of the British Society of Blood & Marrow Transplantation (BSBMT)
M Cummins et al.
BONE MARROW TRANSPLANTATION (2005)
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate
J Cortes et al.
CLINICAL CANCER RESEARCH (2005)
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia
G Rosti et al.
BLOOD (2004)
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-α
HM Kantarjian et al.
BLOOD (2004)
Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants
JR Passweg et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Autoimmune haemolytic anaemia complicating haematopoietic cell transplantation in paediatric patients: high incidence and significant mortality in unrelated donor transplants for non-malignant diseases
TA O'Brien et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia -: A Europe Against Cancer Program
J Gabert et al.
LEUKEMIA (2003)
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
TP Hughes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Outcome of transplantation of highly purified peripheral blood CD34+ cells with T-cell add-back compared with unmanipulated bone marrow or peripheral blood stem cells from HLA-identical sibling donors in patients with first chronic phase chronic myeloid leukemia
AH Elmaagacli et al.
BLOOD (2003)
Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose
C Guglielmi et al.
BLOOD (2002)
Imatinib mesylate (ST1571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase
HM Kantarjian et al.
BLOOD (2002)
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study
M Talpaz et al.
BLOOD (2002)
Bone marrow transplantation depleted of T cells followed by repletion with incremental doses of donor lymphocytes for relapsing patients with chronic myeloid leukemia - A therapeutic strategy
N Novitzky et al.
TRANSPLANTATION (2000)
分享论文
